Vitiligo after alemtuzumab treatment: Secondary autoimmunity is not all about B cells

OBJECTIVE: To report 3 patients with relapsing-remitting multiple sclerosis (RRMS) showing vitiligo after treatment with alemtuzumab. METHODS: Retrospective case series including flow cytometric analyses and T-cell receptor (TCR) sequencing of peripheral blood mononuclear cells. RESULTS: We describe...

Descripción completa

Detalles Bibliográficos
Autores principales: Ruck, Tobias, Pfeuffer, Steffen, Schulte-Mecklenbeck, Andreas, Gross, Catharina C., Lindner, Maren, Metze, Dieter, Ehrchen, Jan, Sondermann, Wiebke, Pul, Refik, Kleinschnitz, Christoph, Wiendl, Heinz, Meuth, Sven G., Klotz, Luisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6329330/
https://www.ncbi.nlm.nih.gov/pubmed/30404783
http://dx.doi.org/10.1212/WNL.0000000000006648

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6329330/
https://www.ncbi.nlm.nih.gov/pubmed/30404783
http://dx.doi.org/10.1212/WNL.0000000000006648

Ejemplares similares